Source link : https://newshealth.biz/health-news/record-survival-seen-with-tarlatamab-maintenance-in-sclc/
In a phase 1b trial, tarlatamab plus an anti-PD-L1 in first-line maintenance achieves a median survival of more than 2 years in extensive-stage small cell lung cancer. Medscape Medical News Source link : https://www.medscape.com/viewarticle/record-survival-seen-tarlatamab-maintenance-sclc-2025a1000oe8?src=rss Author : Publish date : 2025-09-16 07:06:00 Copyright for syndicated content belongs to the linked Source.
The post Record Survival Seen With Tarlatamab Maintenance in SCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-16 07:06:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8